Marketdash
Back to News

Soligenix's Psoriasis Gel Shows Promise in Extended Trial Results

MarketDash Editorial Team
15 hours ago
Soligenix's Phase 2a extension study demonstrates improved skin outcomes for SGX302 gel in psoriasis patients, with strong tolerability and comparable results to earlier formulations.

Soligenix, Inc. (SNGX) shared promising extended results Wednesday from its Phase 2a trial testing SGX302, a synthetic hypericin treatment for mild-to-moderate psoriasis. And here's the interesting part: they've managed to improve the delivery method without sacrificing effectiveness.

The extension phase, called Cohort 3, enrolled four additional patients who used a reformulated topical gel version of synthetic hypericin. The whole point of switching to a gel? Making it easier to spread over larger patches of affected skin. Anyone who's dealt with thick ointments knows this isn't just a convenience thing—it actually matters for whether patients stick with treatment.

The safety profile looked solid. All patients tolerated the gel well, with no drug-related adverse events cropping up during the study.

Here's where the numbers get encouraging. Three patients completed the evaluation (one dropped out for personal reasons unrelated to the treatment), and on average they showed improvements across multiple standard psoriasis measures: the Investigator Global Assessment, the Psoriasis Activity and Severity Index, the simplified psoriasis index, the dermatology life quality index, and the Skindex-29 questionnaire.

One patient hit what's considered a clinical win in psoriasis treatment: achieving "Almost Clear" status on the IGA scale. That same patient saw their PASI score improve by more than 50%, which is a substantial shift in disease severity.

The gel formulation performed as well as or better than the earlier ointment version, which makes sense given that both release the active ingredient similarly. The difference is that patients can actually apply the gel more easily, which could translate to better real-world adherence.

The exploratory phase has essentially confirmed what researchers hoped: SGX302 can improve psoriasis lesions, fitting with the broader success photodynamic therapies have shown for this condition. The potential advantage here is offering a treatment option that's non-carcinogenic and non-mutagenic for the thicker plaques characteristic of psoriasis.

Price Action: Soligenix stock dropped 21.05% to $1.21 Wednesday.

Back to News

Soligenix's Psoriasis Gel Shows Promise in Extended Trial Results

MarketDash Editorial Team
15 hours ago
Soligenix's Phase 2a extension study demonstrates improved skin outcomes for SGX302 gel in psoriasis patients, with strong tolerability and comparable results to earlier formulations.

Soligenix, Inc. (SNGX) shared promising extended results Wednesday from its Phase 2a trial testing SGX302, a synthetic hypericin treatment for mild-to-moderate psoriasis. And here's the interesting part: they've managed to improve the delivery method without sacrificing effectiveness.

The extension phase, called Cohort 3, enrolled four additional patients who used a reformulated topical gel version of synthetic hypericin. The whole point of switching to a gel? Making it easier to spread over larger patches of affected skin. Anyone who's dealt with thick ointments knows this isn't just a convenience thing—it actually matters for whether patients stick with treatment.

The safety profile looked solid. All patients tolerated the gel well, with no drug-related adverse events cropping up during the study.

Here's where the numbers get encouraging. Three patients completed the evaluation (one dropped out for personal reasons unrelated to the treatment), and on average they showed improvements across multiple standard psoriasis measures: the Investigator Global Assessment, the Psoriasis Activity and Severity Index, the simplified psoriasis index, the dermatology life quality index, and the Skindex-29 questionnaire.

One patient hit what's considered a clinical win in psoriasis treatment: achieving "Almost Clear" status on the IGA scale. That same patient saw their PASI score improve by more than 50%, which is a substantial shift in disease severity.

The gel formulation performed as well as or better than the earlier ointment version, which makes sense given that both release the active ingredient similarly. The difference is that patients can actually apply the gel more easily, which could translate to better real-world adherence.

The exploratory phase has essentially confirmed what researchers hoped: SGX302 can improve psoriasis lesions, fitting with the broader success photodynamic therapies have shown for this condition. The potential advantage here is offering a treatment option that's non-carcinogenic and non-mutagenic for the thicker plaques characteristic of psoriasis.

Price Action: Soligenix stock dropped 21.05% to $1.21 Wednesday.